The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of the multi-kinase inhibitor regorafenib in the Pediatric Preclinical Testing Consortium osteosarcoma, rhabdomyosarcoma, and Ewing sarcoma in vivo models.
 
Douglas James Harrison
No Relationships to Disclose
 
Jonathan Benjamin Gill
Consulting or Advisory Role - Celgene (I); Legend Biotech (I); Puma Biotechnology (I)
 
Michael Roth
Research Funding - Eisai
 
Wendong Zhang
No Relationships to Disclose
 
Beverly Teicher
No Relationships to Disclose
 
Stephen W Erickson
No Relationships to Disclose
 
Gregory Gatto
No Relationships to Disclose
 
Raushan Kurmasheva
No Relationships to Disclose
 
Peter Houghton
No Relationships to Disclose
 
Malcolm A. Smith
No Relationships to Disclose
 
E. Anders Kolb
No Relationships to Disclose
 
Richard Greg Gorlick
Research Funding - Eisai (Inst)